Investment Analysts’ Recent Ratings Changes for Zimmer Biomet (ZBH)

Zimmer Biomet (NYSE: ZBH) recently received a number of ratings updates from brokerages and research firms:

• 8/10/2026 – Zimmer Biomet had its price target raised by Canaccord Genuity Group Inc. from $83.00 to $100.00. They now have a “hold” rating on the stock.
• 8/8/2026 – Zimmer Biomet was downgraded by Wall Street Zen from “buy” to “hold”.
• 8/6/2026 – Zimmer Biomet had its price target raised by Truist Financial Corporation from $92.00 to $106.00. They now have a “hold” rating on the stock.
• 8/6/2026 – Zimmer Biomet was given a new $104.00 price target by Robert W. Baird.
• 8/6/2026 – Zimmer Biomet had its “buy” rating reaffirmed by UBS Group AG. They now have a $120.00 price target on the stock.
• 8/6/2026 – Zimmer Biomet had its price target raised by Sanford C. Bernstein from $91.00 to $93.00. They now have a “market perform” rating on the stock.
• 8/6/2026 – Zimmer Biomet had its “market perform” rating reaffirmed by BMO Capital Markets. They now have a $96.00 price target on the stock.
• 8/6/2026 – Zimmer Biomet had its price target raised by Royal Bank Of Canada from $101.00 to $110.00. They now have an “outperform” rating on the stock.
• 8/6/2026 – Zimmer Biomet had its price target raised by Stifel Nicolaus from $105.00 to $110.00. They now have a “buy” rating on the stock.
• 8/5/2026 – Zimmer Biomet had its “hold” rating reaffirmed by Needham & Company LLC.
• 8/4/2026 – Zimmer Biomet was upgraded by Weiss Ratings from “sell (d+)” to “hold (c-)”.
• 7/28/2026 – Zimmer Biomet is now covered by UBS Group AG. They set a “buy” rating and a $115.00 price target on the stock.
• 7/28/2026 – Zimmer Biomet is now covered by UBS Group AG. They set a “buy” rating and a $115.00 price target on the stock.
• 7/27/2026 – Zimmer Biomet was downgraded by Zacks Research from “hold” to “strong sell”.
• 7/25/2026 – Zimmer Biomet was upgraded by Wall Street Zen from “hold” to “buy”.
• 7/20/2026 – Zimmer Biomet was downgraded by Weiss Ratings from “hold (c-)” to “sell (d+)”.
• 7/8/2026 – Zimmer Biomet is now covered by BMO Capital Markets. They set a “market perform” rating and a $95.00 price target on the stock.
• 7/8/2026 – Zimmer Biomet was upgraded by BMO Capital Markets to “hold”.
• 7/6/2026 – Zimmer Biomet had its “hold (c-)” rating reaffirmed by Weiss Ratings.
• 7/4/2026 – Zimmer Biomet was downgraded by Wall Street Zen from “buy” to “hold”.

Insiders Place Their Bets

In related news, insider Sang Yi sold 5,000 shares of the firm’s stock in a transaction that occurred on Friday, May 29th. The stock was sold at an average price of $82.64, for a total transaction of $413,200.00. Following the completion of the transaction, the insider owned 27,251 shares of the company’s stock, valued at $2,252,022.64. This trade represents a 15.50% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 1.28% of the stock is currently owned by company insiders.

Zimmer Biomet (NYSE: ZBH) is a global medical device company focused on musculoskeletal healthcare. Headquartered in Warsaw, Indiana, the company designs, manufactures and markets a broad portfolio of products used to treat joint disorders, bone disorders and related conditions. Its customer base includes orthopaedic and dental surgeons, hospitals, ambulatory surgery centers and other healthcare providers that rely on implants, instruments and related services for reconstructive and restorative procedures.

The company’s product offerings span joint replacement systems for hips, knees and shoulders; trauma and extremities implants; spine and thoracic solutions; dental and craniomaxillofacial implants and prosthetics; and sports medicine devices.